Fulgent Genetics appoints Reggie Groves to board, cures Nasdaq audit committee deficiency

Fulgent Genetics, Inc.

Reggie Groves appointed to Fulgent Board effective Jan 3, 2023; serves on Audit, Compensation, and Nominating/Governance committees.
Appointment resolves non-compliance with Nasdaq Rule 5605 requiring three independent directors on Audit Committee (disclosed Nov 18, 2022).
Groves brings 13 years at Medtronic and experience as CFO/COO at Stimwave, CEO at REVA Medical, and board service at AtriCure.
Groves will receive standard compensation per Non-Employee Director Compensation Policy and entered indemnification agreement.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Regina Groves

Director

FLGT · Fulgent Genetics, Inc.

Effective: 2023-01-03
Filed: January 3, 2023, 6:59 PM ET

On January 3, 2023, the Board of Directors (the “Board”) of the Fulgent Genetics, Inc. (the “Company”) appointed Ms. Regina (“Reggie”) Groves to serve as a member of the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Regina Groves was appointed as Director at Fulgent Genetics, Inc..

Action: appointed
Role: Director

Exact text from the filing

On January 3, 2023, the Board of Directors (the “Board”) of the Fulgent Genetics, Inc. (the “Company”) appointed Ms. Regina (“Reggie”) Groves to serve as a member of the Board.

View on SEC.gov

Fulgent Genetics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-000048

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.